Literature DB >> 17721284

Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study.

Anna Maria Buccoliero1, Chiara Francesca Gheri, Francesca Castiglione, Franco Ammannati, Pasquale Gallina, Antonio Taddei, Francesca Garbini, Duccio Rossi Degl'Innocenti, Luisa Arganini, Nicola Di Lorenzo, Pasquale Mennonna, Gian Luigi Taddei.   

Abstract

One of the most common chromosomal regions implicated in the meningiomas tumorigenesis is 22q12 where the neurofibromatosis 2 (NF2) gene resides. The NF2 tumor-suppressor gene encodes for the merlin/schwannomin protein, which is responsible for the inherited disease neurofibromatosis 2. NF2 gene mutations predominantly occur in transitional and fibroblastic meningiomas, whereas the meningothelial variant is less affected. Secretory meningioma is an infrequent meningioma subtype. Its most typical morphologic feature is the presence of intracytoplasmic or extracytoplasmic round hyaline, eosinophilic, and periodic acid Shiff-positive bodies in a lesion frequently otherwise classifiable as meningothelial meningioma. This study reviews the immunohistochemical merlin expression in 14 consecutive secretory meningiomas. Our purpose was to investigate if secretory meningiomas, analogous to meningothelial meningiomas, follow a molecular route of pathogenesis independent of the neurorofibromatosis 2 gene-associated pathway. All meningiomas showed positive immunocoloration involving the majority of the hyaline inclusions and secretory cells; in 12 (86%) meningiomas, a positive immunoreaction was also documented in nonsecretory tumoral cells. Our results may indicate a molecular, besides morphologic, similarity between secretory and meningothelial meningiomas: the almost constant merlin immunohistochemical expression in our series gives evidence for a possible NF2 gene-independent pathogenesis in secretory meningiomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721284     DOI: 10.1097/01.pai.0000213114.27978.3a

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  5 in total

1.  Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients.

Authors:  Xiaogang Tao; Kun Wang; Jinqian Dong; Zonggang Hou; Zhen Wu; Junting Zhang; Baiyun Liu
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

2.  Secretory meningiomas: a benign subgroup causing life-threatening complications.

Authors:  Jan Regelsberger; Christian Hagel; Pedram Emami; Thorsten Ries; Oliver Heese; Manfred Westphal
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

3.  Epithelial differentiation with microlumen formation in meningioma: diagnostic utility of NHERF1/EBP50 immunohistochemistry.

Authors:  Maria-Magdalena Georgescu; Adriana Olar; Bret C Mobley; Phyllis L Faust; Jack M Raisanen
Journal:  Oncotarget       Date:  2018-06-19

4.  Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.

Authors:  B R Ongaratti; C B O Silva; G Trott; T Haag; C G S Leães; N P Ferreira; M C Oliveira; J F S Pereira-Lima
Journal:  Braz J Med Biol Res       Date:  2016-03-18       Impact factor: 2.590

5.  Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females.

Authors:  Agus Supartoto; Muhammad Bayu Sasongko; Datu Respatika; Indra Tri Mahayana; Suhardjo Pawiroranu; Hari Kusnanto; Dhimas Hari Sakti; Prima Sugesty Nurlaila; Didik Setyo Heriyanto; Sofia Mubarika Haryana
Journal:  Front Oncol       Date:  2019-01-09       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.